Compare HAIN & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HAIN | IMUX |
|---|---|---|
| Founded | 1993 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 99.6M | 85.8M |
| IPO Year | 1993 | N/A |
| Metric | HAIN | IMUX |
|---|---|---|
| Price | $1.18 | $0.59 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | $2.91 | ★ $6.00 |
| AVG Volume (30 Days) | ★ 1.5M | 1.3M |
| Earning Date | 11-07-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,533,067,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.33 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.00 | $0.56 |
| 52 Week High | $7.96 | $1.39 |
| Indicator | HAIN | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 53.79 | 33.23 |
| Support Level | $1.00 | $0.58 |
| Resistance Level | $1.24 | $0.70 |
| Average True Range (ATR) | 0.06 | 0.04 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 77.12 | 3.55 |
The Hain Celestial Group Inc is a health and wellness company. It makes natural and organic food and personal-care products. The company offers products across various categories such as snacks, baby & kids food, beverages, meal preparation, and personal care through brands like Garden Veggie Snacks, Terra chips, Garden of Eatin snacks, Hartley's Jelly, and Celestial Seasonings teas, among others. It operates under two reportable segments: North America and International. The majority of its revenue is derived from the North America segment, which represents the sale of its products in the United States and Canada. The International segment includes the sale of its products in the United Kingdom and the Western European region.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.